IGX12
Infertility
Pre-clinicalActive
Key Facts
About Igyxos Biotherapeutics
Igyxos Biotherapeutics is a private, preclinical-stage biotech focused on developing first-in-class monoclonal antibody therapies for infertility. Its lead candidate, IGX12, is designed to boost the bioactivity of Follicle Stimulating Hormone (FSH) to improve the efficacy of assisted reproductive technologies. The company leverages a unique scientific approach spun out of earlier animal health research and is backed by French institutional investors including BPI France, Go Capital, and UI Investissement.
View full company profileTherapeutic Areas
Other Infertility Drugs
| Drug | Company | Phase |
|---|---|---|
| GONAL-f (follitropin alfa) | EMD Serono | Approved |